Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Eylea
Eylea
The top 15 blockbuster patent expirations coming this decade
Fierce Pharma
Mon, 07/12/21 - 11:08 am
patents
patent cliff
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Revlimid
Pfizer
Eliquis
Regeneron
Eylea
JNJ
Stelara
Opdivo
GSK
Dolutegravir
Ibrance
Januvia
Eli Lilly
Trulicity
Novo Nordisk
Victoza
Amgen
Prolia
Xgeva
Novartis
Cosentyx
Takeda
Entyvio
Regeneron’s golden goose Eylea may stave off biosimilar competition until 2024 or beyond
Endpoints
Tue, 05/4/21 - 10:39 am
Regeneron
Eylea
biosimilars
macular degeneration
Regeneron shoots for longer Eylea dosing interval in diabetic retinopathy with NIH data
Fierce Pharma
Fri, 04/2/21 - 10:55 am
Regeneron
FDA
Eylea
diabetic retinopathy
NIH
Bayer unveils first look at its post-Xarelto, post-Eylea life—and it's better than expected
Fierce Pharma
Wed, 03/10/21 - 10:49 pm
Bayer
Xarelto
Eylea
patents
Stivarga
Verquvo
Roche eyes FDA filing after bispecific matches Eylea again
Fierce Biotech
Mon, 01/25/21 - 10:44 am
Roche
bispecifics
Regeneron
Eylea
clinical trials
faricimab
wet age-related macular degeneration
Bayer pharma chief admits to unfillable revenue gap despite potential blockbuster launches
Fierce Pharma
Mon, 01/18/21 - 01:26 pm
Bayer
Eylea
Xalreto
Roche eyes an uncertain market for faricimab
EP Vantage
Tue, 12/22/20 - 10:49 am
Roche
faricimab
diabetic macular edema
Regeneron
Eylea
Roche's bispecific matches Regeneron's Eylea in phase 3 trials
Fierce Biotech
Mon, 12/21/20 - 11:02 am
Roche
faricimab
diabetic macular edema
clinical trials
Regeneron
Eylea
bispecific antibodies
Novartis raises the temp on Eylea rivalry with head-to-head trial win for Beovu in diabetic macular edema
Endpoints
Tue, 12/15/20 - 10:51 am
Regeneron
Eylea
Novartis
Beovu
diabetic macular edema
Novartis says Beovu matched rival Eylea in visual acuity in eye disease
Pharma Live
Mon, 09/14/20 - 10:41 am
Novartis
Beovu
Eylea
Regeneron
diabetic macular edema
clinical trials
Bayer's Eylea shows pandemic resilience, but major China price cut drags on business
Fierce Pharma
Wed, 08/5/20 - 12:07 am
Bayer
earnings
China
pandemic
COVID-19
Eylea
Regeneron vows ‘vigorous’ defense against allegations it paid kickbacks for eye drug
MedCity News
Fri, 06/26/20 - 07:48 pm
Regeneron
Eylea
Massachusetts
kickbacks
macular degeneration
Regeneron vows to fight DOJ lawsuit alleging charity donations were Eylea kickbacks
Fierce Pharma
Wed, 06/24/20 - 11:33 pm
Regeneron
DOJ
Eylea
kickbacks
charity
AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis
Xconomy
Wed, 06/24/20 - 10:14 am
AsclepiX Therapeutics
eye disease
Eylea
Lucentis
macular edema
wet age-related macular degeneration
retinal occulsion
AXT107
Regeneron touts Eylea strength as Novartis rival falters, COVID-19 cuts demand
Fierce Pharma
Tue, 05/5/20 - 01:02 pm
Regeneron
Eylea
Novartis
Beovu
COVID-19
Does Regeneron Pharmaceuticals’ Winning Streak Signal Irrational Exuberance?
Motley Fool
Fri, 04/24/20 - 10:59 am
Regeneron
Eylea
Dupixent
Novartis knocked by safety scare
EP Vantage
Tue, 02/25/20 - 04:55 pm
Novartis
Regeneron
Beovu
Eylea
wet age-related macular degeneration
Regeneron’s Eylea delivers positive two-year results in PANORAMA trial
Pharmaceutical Business Review
Mon, 02/10/20 - 10:13 am
Regeneron
Eylea
diabetic neuropathy
NPDR
clinical trials
Are Novartis and Regeneron seeing the same thing?
BioPharma Dive
Fri, 02/7/20 - 11:42 pm
Novartis
Regeneron
physicians
Eylea
Beovu
Biogen signs marketing deal for two ophthalmology biosimilars
Pharmaforum
Thu, 11/7/19 - 10:16 am
Biogen
ophthalmology
biosimilars
Europe
Japan
Samsung Bioepis
SB11
SB15
Lucentis
Eylea
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
next ›
last »